CannaLean Biotechs Ltd., founded in 2017 and headquartered in Israel,
CannaLean has established an active partnership with our main shareholders:
Mor Research Applications, the tech transfer company of CLALIT HEALTH SERVICES,
The largest HMO in Israel, with over 4.5M members, (14 full-scale hospitals specializing in all fields of medicine, as well as over 2000 community clinics with over 9000 employed physicians).
CannaLean is committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from Dyslipidemia.
CannaLean has 2 indications in it’s clinical trial pipeline:
the first solution is targeting hypercolesterodemia (high cholesterol blood levels) and is estimated tostart on Q1 2020
the second solution is targeting hypertriglyceriddemia (high triglycerides blood levels) and is estimated to start later on 2020
CannaLean has completed various in vivo and pre-clinical studies showing a significant decrease in cholesterol/triglyceride blood levels, demonstrating the potential clinical effect of the novel patent-protected formulation.
A provisional patent named CANNABIDIOL AND CHITOSAN COMPOSITIONS AND METHODS OF USING THE SAME was filed on 2017 by Mor Research Applications, the Tech Transfer Company of Clalit Health Services. a PCT was filed on October 2018 and is now on the international stage.
The patent covers a composition comprising cannabidiol (CBD) and chitosan for improving dyslipidemia and other signs and symptoms of metabolic syndrome.